jump to content

Fachbereich Veterinärmedizin


Service-Navigation

    Publication Database

    Markers for internal neoplasia in the horse (2023)

    Art
    Zeitschriftenartikel / wissenschaftlicher Beitrag
    Autoren
    Drozdzewska, Karolina (WE 17)
    Gehlen, Heidrun (WE 17)
    Quelle
    Veterinary medicine and science
    Bandzählung: 9
    Heftzählung: 1
    Seiten: 132 – 143
    ISSN: 2053-1095
    Sprache
    Englisch
    Verweise
    URL (Volltext): https://onlinelibrary.wiley.com/doi/10.1002/vms3.1042
    DOI: 10.1002/vms3.1042
    Pubmed: 36495211
    Kontakt
    Pferdeklinik

    Oertzenweg 19 b
    14163 Berlin
    +49 30 838 62299 / 62300
    pferdeklinik@vetmed.fu-berlin.de

    Abstract / Zusammenfassung

    The diagnosis of internal neoplasia in horses is challenging. Increased production of hormones physiologic for adult animals (e.g., adrenocorticotropin, norepinephrine, and erythropoietin) or typical for the foetal phase (alpha-fetoprotein, anti-Müllerian hormone, and parathyroid-hormone-related protein) might aid in tumour diagnostics. Thymidine kinase-1 and alkaline phosphatase are examples of intracellular enzymes, whose activity in the blood may increase in some neoplasia cases. Furthermore, inappropriate production of abnormal monoclonal or autologous antibodies can accompany lymphoma and multiple myeloma. Many of those tumour markers lead to clinical or laboratory changes, called paraneoplastic syndromes, such as hypercalcaemia and erythrocytosis.

    The interpretation of the results of the tumour marker measurements in horses is complicated due to many factors affecting the markers’ concentration or activity (e.g., young age, pregnancy, and inflammation) and other diseases triggering the same changes. Moreover, the presence of paraneoplastic syndromes is inconsistent, which leads to low sensitivity of those substances as tumour markers.

    In conclusion, screening for neoplasia in horses is not recommended. The measurement of tumour markers should be performed only in risk groups with suspicious clinical or laboratory findings, and the results should be interpreted with caution. It is advisable to add inflammatory markers to the tumour profile or repeat the measurements.